Page last updated: 2024-08-24

lamivudine and Weight Loss

lamivudine has been researched along with Weight Loss in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Adebisi, SA; Adedeji, NO; Adedeji, TA; Ajeigbe, AK; Ajose, AO; Akande, AA; Fawale, MB; Jeje, OA; Okesina, BA; Smith, OS	1
Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ	1
Erdem Eralp, E; Kalyoncu, D; Urganci, N	1

Trials

1 trial(s) available for lamivudine and Weight Loss

Article	Year
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss	2021

Article

Year

Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.

Journal of acquired immune deficiency syndromes (1999), 2021, 06-01, Volume: 87, Issue:2

Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss

2021

Other Studies

2 other study(ies) available for lamivudine and Weight Loss

Article	Year
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors. Current HIV research, 2022, Volume: 20, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine	2022
Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B. Annals of nutrition & metabolism, 2017, Volume: 71, Issue:1-2 Topics: Adolescent; Anthropometry; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Malnutrition; Nutritional Status; Obesity; Weight Loss	2017

Article

Year

Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.

Current HIV research, 2022, Volume: 20, Issue:6

Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine

2022

Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B.

Annals of nutrition & metabolism, 2017, Volume: 71, Issue:1-2

Topics: Adolescent; Anthropometry; Antiviral Agents; Child; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Hepatitis B, Chronic; Humans; Interferon-alpha; Lamivudine; Malnutrition; Nutritional Status; Obesity; Weight Loss

2017